Successful Treatment of Hereditary Folate Malabsorption With Intramuscular Folinic Acid.


Journal

Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183

Informations de publication

Date de publication:
01 2020
Historique:
received: 18 03 2019
revised: 08 06 2019
accepted: 12 06 2019
pubmed: 3 8 2019
medline: 15 12 2020
entrez: 3 8 2019
Statut: ppublish

Résumé

Hereditary folate malabsorption is a multisystem disease owing to biallelic variants in the gene encoding the proton-coupled folate transporter. Hereditary folate malabsorption is treated with folinic acid, aimed to restore blood and cerebrospinal fluid folate levels. Little is known as to whether oral or intramuscular supplementation of folinic acid is most effective. Here we describe a one-year-old boy with hereditary folate malabsorption presenting with the typical features including failure to thrive, aphthous stomatitis, macrocytic anemia along with severe developmental impairment and epilepsy, as well as a magnetic resonance imaging of the brain showing bilateral occipital, cortical calcifications characteristic of hereditary folate malabsorption. We compared the effect of treatment with oral folinic acid versus intramuscular folinic acid supplementation by measuring plasma and cerebrospinal fluid folate levels. Compared with oral administration, intramuscular treatment resulted in higher folate levels in blood and, most importantly, normalization of folate levels in cerebrospinal fluid. Clinically, nearly all systemic and neurological symptoms resolved. Normal cerebrospinal fluid folate levels can be achieved in individuals with hereditary folate malabsorption with intramuscular (but not with oral) administration of folinic acid.

Sections du résumé

BACKGROUND
Hereditary folate malabsorption is a multisystem disease owing to biallelic variants in the gene encoding the proton-coupled folate transporter. Hereditary folate malabsorption is treated with folinic acid, aimed to restore blood and cerebrospinal fluid folate levels. Little is known as to whether oral or intramuscular supplementation of folinic acid is most effective.
METHODS
Here we describe a one-year-old boy with hereditary folate malabsorption presenting with the typical features including failure to thrive, aphthous stomatitis, macrocytic anemia along with severe developmental impairment and epilepsy, as well as a magnetic resonance imaging of the brain showing bilateral occipital, cortical calcifications characteristic of hereditary folate malabsorption. We compared the effect of treatment with oral folinic acid versus intramuscular folinic acid supplementation by measuring plasma and cerebrospinal fluid folate levels.
RESULTS
Compared with oral administration, intramuscular treatment resulted in higher folate levels in blood and, most importantly, normalization of folate levels in cerebrospinal fluid. Clinically, nearly all systemic and neurological symptoms resolved.
CONCLUSION
Normal cerebrospinal fluid folate levels can be achieved in individuals with hereditary folate malabsorption with intramuscular (but not with oral) administration of folinic acid.

Identifiants

pubmed: 31371121
pii: S0887-8994(19)30289-9
doi: 10.1016/j.pediatrneurol.2019.06.009
pii:
doi:

Substances chimiques

Vitamin B Complex 12001-76-2
Leucovorin Q573I9DVLP

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

62-66

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Charlotte M A Lubout (CMA)

Department of Pediatric Metabolic Diseases, Emma Children's Hospital, Amsterdam Gastro-Enterology & Metabolism Research Institute, Amsterdam University Medical Centres, Amsterdam, The Netherlands.

Susanna M I Goorden (SMI)

Department of Clinical Chemistry, Laboratory of Genetic Metabolic Diseases, Amsterdam University Medical Centres, Amsterdam, The Netherlands.

Karin van den Hurk (K)

Department of Clinical Chemistry, OLVG Lab BV, Amsterdam, The Netherlands.

Bregje Jaeger (B)

Department of Pediatric Neurology, Emma Children's Hospital, Amsterdam University Medical Centres, Amsterdam, The Netherlands.

Nynke G L Jager (NGL)

Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Centres, Amsterdam, The Netherlands.

Silvana van Koningsbruggen (S)

Department of Clinical Genetics, Amsterdam University Medical Centres, Amsterdam, The Netherlands.

Malika Chegary (M)

Department of Pediatrics, OLVG, Amsterdam, The Netherlands.

Clara D M van Karnebeek (CDM)

Department of Pediatric Metabolic Diseases, Emma Children's Hospital, Amsterdam Gastro-Enterology & Metabolism Research Institute, Amsterdam University Medical Centres, Amsterdam, The Netherlands; Department of Clinical Genetics, Amsterdam University Medical Centres, Amsterdam, The Netherlands. Electronic address: c.d.vankarnebeek@amsterdamumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH